TrialThe Lancet. Oncology2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
Jian Zhou et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this paperpooled ittrialcites it